Trial reportDrug design, development and therapy2025
Combined Esketamine and Dexmedetomidine Decreases the Risk of Postoperative Delirium in Neurosurgical Pediatrics: A Randomized Controlled Trial.
Trial report in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Perioperative Use of Dexmedetomidine-esketamine Combination and Transcranial Direct Current Stimulation for Prevention of Neurocognitive Complications in Older Patients After Non-cardiac Surgery: a 2×2 Factorial Trial
Long-term Follow-up of Perioperative Dexmedetomidine-esketamine Combination and Transcranial Direct Current Stimulation for Prevention of Neurocognitive Complications in Older Patients After Non-cardiac Surgery
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and Safety of Dexmedetomidine-Esketamine Versus Dexmedetomidine Alone as Premedication for Pediatric Anesthesia Induction: A Systematic Review, Meta-Analysis, and Trial Sequential Analysis.Paediatric anaesthesia · 2026Pooled it
- Pain control or brain protection: which mechanism defines esketamine?Anaesthesia · 2026Article
- Pain control or brain protection with esketamine: a reply.Anaesthesia · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Present study was designed to investigate whether combined esketamine and dexmedetomidine could decrease the risk of postoperative delirium in neurosurgical pediatric. Patients and Methods: In this prospective randomized controlled study, pediatrics (aged 2-16 years) who were scheduled for selective neurosurgery were enrolled. Patients were randomized to receive combined esketamine (0.5 mg/kg) and dexmedetomidine (0.5 μg/kg) or normal saline as placebo at anesthesia induction. Primary outcome was the incidence of delirium within postoperative the first five days which was assessed twice daily using the Cornell Assessment of Pediatric Delirium (CAPD). CAPD≥ 10 at any assessment point was considered as delirium. Secondary outcomes included the incidence of emergence delirium, non-delirium complications within postoperative 30 days, postoperative length of in-hospital stay, and medical cost during hospitalization. The change of systematic inflammation was reflected by Neutrophil-to-Lymphocyte Ratio. Results: From July 2021 to March 2023, 270 patients were screened, and 190 patients were randomized. Median age of enrolled patients was similar between two groups (63.0 [43.3, 111.3] vs 70.0 [46.3, 114.8] months, P = 0.883). Patients in esketamine-dex group suffered lower incidence of postoperative delirium than control group (intention-to-treat analysis: 22.8% [21/92] vs 38.0% [35/92], RR = 0.600, 95% CI 0.380-0.948, P = 0.025; per-protocol analysis: 22.0% [20/91] vs 38.2% [34/89], RR = 0.575, 95% CI 0.360-0.919, P = 0.018). The incidence of emergence delirium was lower in esketamine-dex group than control group (20.7% [19/92] vs 50.0% [46/92], RR = 0.413, 95% CI 0.263-0.648, P < 0.001). Patients in esketamine-dex group had lower medical cost (P < 0.001), and there was no statistical significance in the incidence of non-delirium complications within postoperative 30 days and postoperative length of in-hospital stay. The neutrophil-to-lymphocyte ratios at postoperative first and third day were comparable between two groups. Safety outcomes such as bradycardia and hypotension were comparable between groups. Conclusion: Combined esketamine and dexmedetomidine could decrease the risk postoperative delirium and emergence delirium in pediatrics after neurosurgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.